TEVA PHARMACEUTICAL INDUSTRIES LIMITED
At today's price, TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) is priced for +6.0% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Teva is a turnaround: a large but shrinking generics base is being offset by fast-growing branded CNS drugs, led by Austedo, which grew 41% to $578 million in Q1 2026. [Source: Q1 2026 earnings release] • The biggest issue is the balance sheet legacy: the Altman score of 0.68 sits in distress territory from years of acquisition debt and legal settlements, and management has committed to reaching 2x net debt to EBITDA by 2027. [Source: Q1 2026 earnings call] • Watch the branded ramp against gen
Is TEVA overvalued? See what's priced in →
634 institutional managers reported holding TEVA in 13F filings for the quarter ended 2026-03-31. Together they hold about 57% of the company; the top 10 hold 33%. 82 opened new positions that quarter. Held by BlackRock, WCM Investment Management, FMR (Fidelity), among others. On the short side, 33.3M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (5.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
TEVA's share count grew 4.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at TEVA over the trailing three years: 2025: 1 buy totaling $21k. 23 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
TEVA's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-03 | +15.4% | -2.4% |
| 2023-11-10 | -3.0% | +30.4% |
| 2024-02-13 | +6.2% | +1.3% |
| 2024-05-09 | +14.7% | +6.9% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
TEVA's latest 8-K filings: 2026-05-28 (items 5.07); 2026-04-29 (items 2.02, 7.01, 9.01); 2026-01-28 (items 2.02, 9.01); 2026-01-12 (items 2.02, 9.01); 2025-12-11 (items 1.01, 2.03, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.